Loft, Henrik

Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology

Treatment of Major DepressionMental Health Treatment and Access

Cited by 254

Memantine for Agitation/Aggression and Psychosis in Moderately Severe to Severe Alzheimer's Disease: A Pooled Analysis of 3 Studies

Wilcock, G. K., Ballard, C. G., Cooper, J. A., & Loft, H. (2008) · The Journal of Clinical Psychiatry

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 253

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

Alvarez, E., Perez, V., Dragheim, M., Loft, H., & Artigas, F. (2012) · The International Journal of Neuropsychopharmacology

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 225

Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis

Gauthier, S., Loft, H., & Cummings, J. (2008) · International Journal of Geriatric Psychiatry

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 220

The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials

McIntyre, R., Harrison, J., Loft, H., Jacobson, W., & Olsen, C. (2016) · International Journal of Neuropsychopharmacology

Treatment of Major DepressionSchizophrenia research and treatment

Cited by 185

Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder

Boulenger, J.-P., Loft, H., & Olsen, C. K. (2014) · International Clinical Psychopharmacology

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 176

Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment

Fagiolini, A., Florea, I., Loft, H., & Christensen, M. C. (2021) · Journal of Affective Disorders

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 127

A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder

Boulenger, J.-P., Loft, H., & Florea, I. (2012) · Journal of Psychopharmacology

Treatment of Major DepressionBipolar Disorder and Treatment

Cited by 127

A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder

Montgomery, S. A., Nil, R., Dürr-Pal, N., Loft, H., & Boulenger, J.-P. (2005) · The Journal of Clinical Psychiatry

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesTreatment of Major Depression

Cited by 115

Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder

McIntyre, R. S., Florea, I., Tonnoir, B., Loft, H., Lam, R. W., & Christensen, M. C. (2017) · The Journal of Clinical Psychiatry

Treatment of Major DepressionSchizophrenia research and treatment

Cited by 100

Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study

Saragoussi, D., Touya, M., Haro, J. M., Jönsson, B., Knapp, M., Botrel, B., Florea, I., Loft, H., & Rive, B. (2017) · Neuropsychiatric Disease and Treatment

Treatment of Major DepressionMental Health Treatment and Access

Cited by 63

PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram

Lundberg, J., Christophersen, J. S., Petersen, K. B., Loft, H., Halldin, C., & Farde, L. (2007) · The International Journal of Neuropsychopharmacology

Neurotransmitter Receptor Influence on BehaviorTreatment of Major Depression

Cited by 55

Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting

Christensen, M. C., Fagiolini, A., Florea, I., Loft, H., Cuomo, A., & Goodwin, G. M. (2021) · Journal of Affective Disorders

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 52

The effect of vortioxetine on health-related quality of life in patients with major depressive disorder

Florea, I., Danchenko, N., Brignone, M., Loft, H., Rive, B., & Abetz-Webb, L. (2015) · Clinical Therapeutics

Treatment of Major DepressionHealth Systems, Economic Evaluations, Quality of Life

Cited by 35

Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma

Christensen, M. C., Florea, I., Loft, H., & McIntyre, R. S. (2020) · Journal of Affective Disorders

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 26